Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma

Yaya Chu, Aliza Gardenswartz, Amanda M. Termuhlen, Mitchell S. Cairo

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.

Original languageEnglish (US)
Pages (from-to)1055-1070
Number of pages16
JournalBritish journal of haematology
Volume185
Issue number6
DOIs
StatePublished - Jun 2019

Keywords

  • B-cell non-Hodgkin lymphoma
  • IL-15 superagonist
  • cellular immunotherapy
  • chimeric antigen receptor
  • stem cell transplantation

Fingerprint Dive into the research topics of 'Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma'. Together they form a unique fingerprint.

  • Cite this